The incidence of erectile dysfunction was higher among GLP-1RA users at 35.2 cases per 1,000 person-years
PubMed: 18165383 Compare AOD-9604 About this article: Written by the PeptideMark Research Team and reviewed by Richard Hayes, Editor-in-Chief
ScienceDirect , Gofron, Krzysztof Ksawery, Andrzej Wasilewski, and Sylwia Magorzewicz
There is no established safety data for the combination in any population, so the honest position is that contraindication data does not exist at the combination level
Peri-menopause and menopause are natural phases of a womans life, and understanding the associated hormonal imbalances is crucial for maintaining overall health
When starting semaglutidea GLP-1 receptor agonist clinically proven to reduce weight and improve metabolic healthmany patients ask whether combining the two is safe